Advertisement
AMLX vs ERAS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and ERAS is a Hold.
AMLX in downward trend: 10-day moving average moved below 50-day moving average on October 05, 2026
The 10-day moving average for AMLX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
AMLX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for AMLX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Oscillator exited the oversold zone, 22 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
AMLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.674) is normal, around the industry mean (43.873). P/E Ratio (2.686) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ERAS's Indicator enters downward trend
The Aroon Indicator for ERAS entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 212 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 59 cases where ERAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ERAS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ERAS's RSI Indicator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on ERAS as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on October 02, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 52 of 56 cases over the following month. The odds of a continued upward trend are 90%.
Following a +13.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 212 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.661) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| AMLX | ERAS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 86% |
| Momentum ODDS (%) | N/A | 2 days ago 86% |
| MACD ODDS (%) | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | N/A | 7 days ago 83% |
| Declines ODDS (%) | 3 days ago 80% | 2 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green while ERAS’s FA Score has 0 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- ERAS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 3 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).
- AMLX’s TA Score: 3 bullish, 4 bearish.
- ERAS’s TA Score: 4 bullish, 4 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а -1.46% price change this week, while ERAS (@Biotechnology) price change was +4.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.71%. For the same industry, the average monthly price growth was -1.84%, and the average quarterly price growth was +12.05%.
The average weekly price growth across all stocks in the @Biotechnology industry was -5.81%. For the same industry, the average monthly price growth was -12.37%, and the average quarterly price growth was -18.43%.
Reported Earning Dates
AMLX is expected to report earnings on Nov 05, 2026.
ERAS is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.71% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-5.81% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SBIT | 31.76 | 1.17 | +3.82% |
| ProShares UltraShort Bitcoin ETF (SBIT) | |||
| FXED | 16.44 | 0.05 | +0.31% |
| Sound Enhanced Fixed Income ETF (FXED) | |||
| NLSI | 58.76 | 0.08 | +0.13% |
| NEOS Long/Short Equity Income ETF (NLSI) | |||
| STEW | 17.69 | N/A | N/A |
| SRH Total Return Fund | |||
| AFIF | 9.26 | -0.01 | -0.11% |
| Anfield Universal Fixed Income ETF (AFIF) | |||